• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

BMJ Open . External validation of the 4C Mortality Score for patients with COVID-19 and pre-existing cardiovascular diseases/risk factors

tetano

Editor, Senior Moderator
BMJ Open


. 2021 Sep 8;11(9):e052708.
doi: 10.1136/bmjopen-2021-052708.
External validation of the 4C Mortality Score for patients with COVID-19 and pre-existing cardiovascular diseases/risk factors


Shunsuke Kuroda[SUP] 1 [/SUP], Shingo Matsumoto[SUP] 2 [/SUP], Takahide Sano[SUP] 3 [/SUP], Takeshi Kitai[SUP] 4 [/SUP], Taishi Yonetsu[SUP] 5 [/SUP], Shun Kohsaka[SUP] 6 [/SUP], Sho Torii[SUP] 7 [/SUP], Takuya Kishi[SUP] 8 [/SUP], Issei Komuro[SUP] 9 [/SUP], Ken-Ichi Hirata[SUP] 10 [/SUP], Koichi Node[SUP] 11 [/SUP], Yuya Matsue[SUP] 12 [/SUP]



Affiliations

Abstract

Objectives: Predictive algorithms to inform risk management decisions are needed for patients with COVID-19, although the traditional risk scores have not been adequately assessed in Asian patients. We aimed to evaluate the performance of a COVID-19-specific prediction model, the 4C (Coronavirus Clinical Characterisation Consortium) Mortality Score, along with other conventional critical care risk models in Japanese nationwide registry data.
Design: Retrospective cohort study.
Setting and participants: Hospitalised patients with COVID-19 and cardiovascular disease or coronary risk factors from January to May 2020 in 49 hospitals in Japan.
Main outcome measures: Two different types of outcomes, in-hospital mortality and a composite outcome, defined as the need for invasive mechanical ventilation and mortality.
Results: The risk scores for 693 patients were tested by predicting in-hospital mortality for all patients and composite endpoint among those not intubated at baseline (n=659). The number of events was 108 (15.6%) for mortality and 178 (27.0%) for composite endpoints. After missing values were multiply imputed, the performance of the 4C Mortality Score was assessed and compared with three prediction models that have shown good discriminatory ability (RISE UP score, A-DROP score and the Rapid Emergency Medicine Score (REMS)). The area under the receiver operating characteristic curve (AUC) for the 4C Mortality Score was 0.84 (95% CI 0.80 to 0.88) for in-hospital mortality and 0.78 (95% CI 0.74 to 0.81) for the composite endpoint. It showed greater discriminatory ability compared with other scores, except for the RISE UP score, for predicting in-hospital mortality (AUC: 0.82, 95% CI 0.78 to 0.86). Similarly, the 4C Mortality Score showed a positive net reclassification improvement index over the A-DROP and REMS for mortality and over all three scores for the composite endpoint. The 4C Mortality Score model showed good calibration, regardless of outcome.
Conclusions: The 4C Mortality Score performed well in an independent external COVID-19 cohort and may enable appropriate disposition of patients and allocation of medical resources.Trial registration number UMIN000040598.

Keywords: COVID-19; epidemiology; respiratory infections.
 
Back
Top Bottom